480 related articles for article (PubMed ID: 25310208)
1. Diagnosis and management of Castleman disease.
Soumerai JD; Sohani AR; Abramson JS
Cancer Control; 2014 Oct; 21(4):266-78. PubMed ID: 25310208
[TBL] [Abstract][Full Text] [Related]
2. Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study.
Sopfe J; Endres A; Campbell K; Hayes K; Trout AT; Liang X; Lorsbach R; O'Brien MM; Cost CR
Pediatr Blood Cancer; 2019 May; 66(5):e27613. PubMed ID: 30680887
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and treatment outcomes of Castleman disease in children: a retrospective cohort in China.
Hu S; Li Z; Wang H; Chen L; Ma Y; Zhu X; Li J; Dong R; Yao W; Dong C; Zhang H; Li K; Dong K; Zhai X
Eur J Pediatr; 2023 Dec; 182(12):5519-5530. PubMed ID: 37782352
[TBL] [Abstract][Full Text] [Related]
4. The French paediatric cohort of Castleman disease: a retrospective report of 23 patients.
Borocco C; Ballot-Schmit C; Ackermann O; Aladjidi N; Delaleu J; Giacobbi-Milet V; Jannier S; Jeziorski E; Maurier F; Perel Y; Piguet C; Oksenhendler E; Koné-Paut I; Galeotti C
Orphanet J Rare Dis; 2020 Apr; 15(1):95. PubMed ID: 32303241
[TBL] [Abstract][Full Text] [Related]
5. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
[TBL] [Abstract][Full Text] [Related]
7. Unicentric Castleman Disease.
Wong RSM
Hematol Oncol Clin North Am; 2018 Feb; 32(1):65-73. PubMed ID: 29157620
[TBL] [Abstract][Full Text] [Related]
8. Castleman Disease: A Multicenter Case Series from Turkey.
Gündüz E; Kırkızlar HO; Ümit EG; Karaman Gülsaran S; Özkocaman V; Özkalemkaş F; Candar Ö; Elverdi T; Küçükyurt S; Paydaş S; Çeneli Ö; Karakuş S; Maral S; Ekinci Ö; İpek Y; Kis C; Güven ZT; Akdeniz A; Celkan T; Eroğlu Küçükdiler AH; Akgün Çağlıyan G; Özçelik Şengöz C; Karataş A; Bulduk T; Özcan A; Belen Apak FB; Canbolat A; Kartal İ; Ören H; Töret E; Özdemir GN; Bakanay Öztürk ŞM
Turk J Haematol; 2022 Jun; 39(2):130-135. PubMed ID: 35176839
[TBL] [Abstract][Full Text] [Related]
9. Overview of Castleman disease.
Dispenzieri A; Fajgenbaum DC
Blood; 2020 Apr; 135(16):1353-1364. PubMed ID: 32106302
[TBL] [Abstract][Full Text] [Related]
10. Clinical, laboratory and imaging findings in Castleman's disease - The subtype decides.
Haap M; Wiefels J; Horger M; Hoyer A; Müssig K
Blood Rev; 2018 May; 32(3):225-234. PubMed ID: 29223447
[TBL] [Abstract][Full Text] [Related]
11. HIV-associated multicentric Castleman disease.
Reddy D; Mitsuyasu R
Curr Opin Oncol; 2011 Sep; 23(5):475-81. PubMed ID: 21760504
[TBL] [Abstract][Full Text] [Related]
12. [Clinical analysis of 30 cases of Castleman disease with different types of thoracic involvement].
Zhang XX; Jiang L; Wang CY; Gu YY; Li LG; Xia TT; Huang Y; Huang PK; Zhang QL
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):149-156. PubMed ID: 32135633
[No Abstract] [Full Text] [Related]
13. Unicentric Castleman disease: A case report of an atypical presentation and successful management.
Muhammad T; Alkheder A; Mazloum A; Almooay A; Naziha L; Shaheen M
Int J Surg Case Rep; 2024 May; 118():109688. PubMed ID: 38669805
[TBL] [Abstract][Full Text] [Related]
14. Castleman disease: Experience from a single institution.
Abraham SS; Narayanan G; Thambi SM; Vasudevan JA; Joy Philip DS; Purushothaman PN; Nair SG; Nair R
Med Int (Lond); 2023; 3(6):56. PubMed ID: 37927353
[TBL] [Abstract][Full Text] [Related]
15. The full spectrum of Castleman disease: 273 patients studied over 20 years.
Oksenhendler E; Boutboul D; Fajgenbaum D; Mirouse A; Fieschi C; Malphettes M; Vercellino L; Meignin V; Gérard L; Galicier L
Br J Haematol; 2018 Jan; 180(2):206-216. PubMed ID: 29143319
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and Management of Castleman Disease.
Abramson JS
J Natl Compr Canc Netw; 2019 Nov; 17(11.5):1417-1419. PubMed ID: 31766018
[TBL] [Abstract][Full Text] [Related]
17. Human Herpesvirus Type 8-positive Multicentric Castleman Disease.
Melikyan AL; Egorova EK; Julhakyan HL; Kovrigina AL; Savchenko VG
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S159-65. PubMed ID: 27133959
[TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.
Nagy A; Bhaduri A; Shahmarvand N; Shahryari J; Zehnder JL; Warnke RA; Mughal T; Ali S; Ohgami RS
Blood Adv; 2018 Mar; 2(5):481-491. PubMed ID: 29496669
[TBL] [Abstract][Full Text] [Related]
19. Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
[TBL] [Abstract][Full Text] [Related]
20. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
Abid MB; Peck R; Abid MA; Al-Sakkaf W; Zhang Y; Dunnill GS; Staines K; Sequeiros IM; Lowry L
Hematol Oncol; 2018 Feb; 36(1):320-323. PubMed ID: 28401573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
